The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells

Table 1 A number of Jakinibs and STAT inhibitors

Drug	Targt	Disease	Status
Ruxolitinib (INC424)	JAK1, JAK2	Polycythemia, Psoriasis (topical), myelofibrosis, Various cancers,	FDA approved
Tofacitinib	JAK3 > JAK1> > (JAK2)	RA, Psoriasis, Spondyloarthropathy, Transplant rejection, ulcerative colitis	FDA approved
Oclacitinib	JAK1	Canine allergic dermatitis	FDA approved
Baricitinib	JAK1, JAK2	RA Psoriasis, diabetic nephropathy, SLE, Atopic dermatitis	Phase III Phase II
Momelitinib	JAK1, JAK2	Myelofibrosis	Phase III
Peficitinib	JAK1, JAK3	RA Psoriasis	Phase III Phase II
INCB039110	JAK1, JAK2	Psoriasis, RA	Phase II
AZD1480	JAK1, JAK2	Myeloproliferative diseases, various cancers	Phase I
ISIS-STAT3Rx (AZD9150)	STAT3	Various cancers	Phase II
OPB-31121	STAT3	Various cancers	Phase I

ISSN: 1478-811X